Generate Biomedicines Inc (GENB) is a clinical-stage biopharmaceutical company that uses an AI-powered platform, called the Generate Platform, to discover and develop protein-based therapeutic candidates. Revenue is derived from collaboration agreements, recorded as collaboration revenue on the income statement, with no product sales reported as of Q1 2026. The company operates at a net loss, funding operations through equity financing, including an initial public offering completed in early 2026 during which convertible preferred stock converted into common stock. The Generate Platform incorporates AI to identify therapeutic candidates, predict biological outcomes, and support drug development programs. As a pre-commercial biotechnology company, Generate Biomedicines depends on partnership and licensing arrangements for near-term revenue, and is subject to the typical drug development pipeline risks including regulatory approval uncertainty and reimbursement dependence on government and private payors. The company filed its 10-Q on May 7, 2026, covering the three months ended March 31, 2026.

Revenue model

Collaboration revenue from partnership and licensing arrangements. No product revenue reported as of Q1 2026 (three months ended March 31, 2026). Deferred revenue, both current and non-current, appears on the balance sheet, indicating upfront payments from collaboration partners recognized over time.

Products and services

The Generate Platform: an AI-integrated drug discovery and development platform used to identify viable therapeutic candidates, predict biological outcomes, and produce reproducible results. The company develops protein-based therapeutic product candidates advanced through this platform.

Customers and end markets

Collaboration partners in the pharmaceutical and biotechnology industry. End markets include human therapeutics subject to regulatory approval and third-party payor reimbursement, including Medicare, Medicaid, and managed care organizations.

Value-chain role

Early-stage drug discovery and development. Generate Biomedicines occupies the research, preclinical, and clinical development portion of the pharmaceutical value chain, relying on collaboration partners for commercialization and on contract manufacturers and third-party providers for manufacturing and clinical operations.

Geographic exposure

The filing references foreign currency exchange impacts and mentions geopolitical risks, but does not specify revenue by geography. Primary regulatory focus appears to be U.S.-based given references to Medicare, Medicaid, and U.S. Regulatory Authorities.

Source: SEC 10-Q, filed 2026-05-07

Industry: Pharmaceutical Preparations